Neumora Therapeutics, Inc. NMRA

NMRA Company Overview

Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company focused on developing precision medicines for brain diseases and neuropsychiatric disorders. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, with a strategy centered on combining neuroscience, data science, genetics, and translational medicine to improve treatment development for conditions that have historically experienced high clinical failure rates. Neumora’s pipeline primarily targets major depressive disorder (MDD), bipolar depression, schizophrenia-related conditions, and neurodegenerative or neuroinflammatory disorders.

The company’s principal revenue model currently consists of research collaborations and financing activities rather than commercial product sales, as its therapeutic candidates remain in clinical development. Its lead programs include navacaprant, a selective kappa opioid receptor antagonist being studied for major depressive disorder, along with additional CNS-focused assets sourced internally and through strategic partnerships. Neumora was launched in 2019 with support from Arch Venture Partners and a portfolio of neuroscience assets assembled through collaborations with biotechnology and pharmaceutical organizations. The company has positioned itself as a data-enabled CNS drug developer seeking to improve patient stratification and biomarker-driven development in psychiatry.